Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. In an ...
areas that are important to public health. “The CFAST initiative continues to drive progress in developing therapeutic area standards for some of the world’s most pressing health concerns,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results